Portal Hypertension SIG: Mechanisms of Regression of Portal Hypertension

5 (1 vote)

Recorded On: 11/09/2018

There has been no new drug class in the treatment of portal hypertension in over 25 years. But recent advancements in our understanding of the pathophysiology of portal hypertension and its potential regression have informed development of oninvasive biomarkers and revealed exciting new targets for therapy. This program will discuss key developments in the basic biology of portal hypertension and how this knowledge is being applied to develop novel biomarkers and therapeutic approaches for portal hypertension.

Jonathan Fallowfield

Jordi Gracia-Sancho

Annalisa Berzigotti

Ramon Bataller

Guadalupe Garcia-Tsao

Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

Key:

Complete
Failed
Available
Locked
Session I: Cellular and Molecular Basis for Portal Hypertension Regression
Regression of portal hypertension: dynamic vs. structural components
Open to view video.
Open to view video. Presenter: Jonathan Fallowfield
You must register to access.
Sinusoidal communications and potential role in portal hypertension regression
Open to view video.
Open to view video. Presenter: Jordi Gracia-Sancho
You must register to access.
Pathophysiological rationale for non-invasive biomarkers of portal hypertension regression
Open to view video.
Open to view video. Presenter: Annalisa Berzigotti
You must register to access.
Session II: Spontaneous vs. Drug-Promoted Regression of Portal Hypertension
Evidence for regression of portal hypertension following disease-specific treatment
Open to view video.
Open to view video. Presenter: Ramon Bataller
You must register to access.
Targeted drug therapy for regression of portal hypertension: is it really feasible?
Open to view video.
Open to view video. Presenter: Guadalupe Garcia-Tsao
You must register to access.
Panel Discussion/Q&A
Open to view video.
Open to view video.
You must register to access.
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.
You must register to access.